Search Patents
  • Patent number: 5508199
    Abstract: A cloned cDNA encoding debrisoquine 4-hydroxylase gene and a probe for identifying humans having a genetic defect in the metabolism of a certain class of drugs of which debrisoquine is a model, have been prepared. Testing of new drugs and of humans by a simple assay has also been described.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: April 16, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank J. Gonzalez, James P. Hardwick, Harry V. Gelboin, Urs A. Meyer
  • Patent number: 5164313
    Abstract: The present invention is related to the construction and application of vaccinia virus containing DNA sequences for encoding and efficient expression of enzymatically active cytochrome P-450 polypeptides in mammalian cells. Preparation and use of pure P1-450 and P3-450 cytochromes have been described.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: November 17, 1992
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Narayana Battula, Frank J. Gonzalez, Bernard Moss
  • Patent number: 5660986
    Abstract: Non-tumorigenic, stable, human bronchial and liver epithelial cell lines are provided wherein the cell lines are capable of expressing human cytochrome P450 genes which have been inserted into the cell lines. Also provided are methods and kits for identifying potential mutagens, cytotoxins, carcinogens, chemotherapeutic and chemo-preventive agents utilizing these cell lines.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 26, 1997
    Inventors: Curtis C. Harris, Harry V. Gelboin, Frank J. Gonzalez, Katharine C. Mace, Andrea M. A. Pfeifer
  • Patent number: 5506138
    Abstract: The present invention is related to the construction and application of vaccinia virus containing DNA sequences for encoding and efficient expression of enzymatically active cytochrome P-450 polypeptides in mammalian cells. Preparation and use of pure P1-450 and P3-450 cytochromes have been described.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: April 9, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Narayana Battula, Frank J. Gonzalez, Bernard Moss
  • Patent number: 5356806
    Abstract: Non-tumorigenic, human bronchial epithelial cell lines are provided wherein the cell lines are capable of expressing cytochrome P450 genes which have been inserted into the cell lines. Also provided are methods and kits for identifying potential mutagens, cytotoxins, carcinogens, and chemotherapeutic agents utilizing these cell lines.
    Type: Grant
    Filed: April 13, 1992
    Date of Patent: October 18, 1994
    Assignees: The United States of America as represented by the Department of Health and Human Services, Nestec, S.A.
    Inventors: Curtis C. Harris, Harry V. Gelboin, Frank J. Gonzalez, Andrea M. A. Pfeifer
  • Patent number: 5726041
    Abstract: An improved method for measuring the activity of a promoter sequence in a mammalian cell using a reporter gene is provided. The improvement involves using a reporter cassette containing a DNA sequence encoding a cytochrome P450 with a polyadenylation signal sequence as the reporter gene. Compositions containing the cytochrome P450 reporter cassette also are provided.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: March 10, 1998
    Assignees: Gentest Corporation, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Charles L. Chrespi, Bruce W. Penman, Frank J. Gonzalez, Harry V. Gelboin, Talia Sher
  • Patent number: 5506131
    Abstract: Non-tumorigenic, stable, human bronchial and liver epithelial cell lines are provided wherein the cell lines are capable of expressing human cytochrome P450 genes which have been inserted into the cell lines. Also provided are methods and kits for identifying potential mutagens, cytotoxins, carcinogens, chemotherapeutic and chemo-preventive agents utilizing these cell lines.
    Type: Grant
    Filed: May 19, 1993
    Date of Patent: April 9, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Curtis C. Harris, Harry V. Gelboin, Frank J. Gonzalez, Katharine C. Mace, Andrea M. A. Pfeifer
  • Publication number: 20050054009
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Application
    Filed: September 14, 2004
    Publication date: March 10, 2005
    Applicant: National Institutes of Health
    Inventors: Harry Gelboin, Kristopher Krausz, Frank Gonzalez
  • Publication number: 20070154971
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Application
    Filed: March 7, 2007
    Publication date: July 5, 2007
    Applicant: National Institutes of Health
    Inventors: Harry Gelboin, Kristopher Krausz, Frank Gonzalez
  • Publication number: 20020115124
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C 19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Application
    Filed: September 10, 2001
    Publication date: August 22, 2002
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Publication number: 20050075487
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.
    Type: Application
    Filed: July 9, 2003
    Publication date: April 7, 2005
    Applicant: Health and Human Services, Department of United States of America
    Inventors: Harry Gelboin, Kristopher Krausz, Frank Gonzalez
  • Patent number: 6908738
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: June 21, 2005
    Assignee: National Institute of Health
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Patent number: 7262018
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: August 28, 2007
    Assignee: National Institutes of Health
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Patent number: 7682800
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: March 23, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Patent number: 6060253
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2D6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2D6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful in methods for screening drugs for metabolism by cytochrome P450 2D6, and in methods of screening individuals for a poor metabolizing human P450 2D6 phenotype.
    Type: Grant
    Filed: January 23, 1997
    Date of Patent: May 9, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez, Kristopher W. Krausz
  • Patent number: 7524939
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: April 28, 2009
    Assignee: United States of America as represented by Department of Health and Human Services
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Patent number: 6623960
    Abstract: The invention provides monoclonal antibodies to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: September 23, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Patent number: 6335428
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: January 1, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez, Tian J. Yang
  • Patent number: 6323325
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez
  • Patent number: 5939530
    Abstract: Antigen binding polypeptides that specifically bind human cytochrome P450 3A3, 3A4, and 3A5 and that specifically inhibit the enzyme activity of human cytochrome P450 3A3, 3A4, and 3A5 are described. Antigen binding polypeptides that specifically bind to human cytochrome P450 3A3 and 3A4 are also described. Antigen binding polypeptides which specifically bind to human cytochrome P450 2E1 and which specifically inhibit the enzyme activity of human cytochrome P450 2E1 are described. Antigen binding polypeptides which specifically bind to human cytochrome P450 2E1 are also described. Methods of determining the contribution of human cytochrome P450s to the metabolism of compounds, using the antigen binding polypeptides of the invention, are also described.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: August 17, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez
Narrow Results

Filter by US Classification